What stage does Kae Capital invest at?

Kae Capital invests at pre-seed to pre-Series A stage.

What is Kae Capital's cheque size?

$1.5M to $2M initial investment.

July 2026 – Kae Capital

How to Think About Pricing in India

Posted on July 24, 2026July 24, 2026 by Kae Team

Price is a signal before it is a number.

In most markets, a buyer evaluates a product and then reacts to the price. In Indian B2B markets, particularly at the enterprise and upper-SMB level, the price is part of the evaluation. It tells the buyer something about how the seller sees the product’s value, whether the company is financially stable, and how the relationship will be conducted. Founders who treat pricing purely as a revenue optimization problem miss this dimension entirely.

This guide is about the structural realities of pricing in India that most frameworks do not address, and the specific patterns that compound into problems if not understood early.

The Buyer’s Reference Point Is Not What You Think

The instinct when entering an Indian market is to benchmark against what comparable products charge in the US and apply a discount. The discount is usually too large, and the reference is usually wrong.

Most Indian B2B buyers are not comparing your product to its US equivalent. They are comparing it to what they currently do. And what they currently do, in a large part of the Indian economy, is employ people.

A procurement manager at a mid-size manufacturer is not thinking about what SAP charges. She is thinking about the two employees who currently manage procurement through phone calls and spreadsheets, what they cost, and what errors they produce. A logistics operator is not benchmarking against US fleet management software. He is calculating whether your product is cheaper than the coordinator who calls drivers every morning to confirm dispatch.

When the incumbent is a person rather than a product, the price comparison changes entirely. The cost of manual labor in India is not low: a competent junior employee in a Tier 1 city costs ₹25,000 to ₹40,000 per month inclusive of provident fund, insurance, and overhead. Two employees managing a process your software replaces represent ₹50,000 to ₹80,000 in monthly cost. A founder who prices their product at ₹8,000 per month because they are nervous about India’s price sensitivity is leaving most of the available value on the table and inadvertently telling the buyer that the product is not serious.

The right starting point is a conversation with the buyer about their current process: how many people are involved, how much time it takes, what errors it produces, and what those errors cost. That conversation establishes a value anchor that makes almost any reasonable software price look like a good deal.

Low Prices Communicate Risk

There is a counterintuitive dynamic in Indian enterprise sales that experienced founders know and early-stage founders regularly discover the hard way.

When an early-stage company prices significantly below what an enterprise buyer expects for a product that solves a serious problem, the buyer’s first reaction is often not relief. It is suspicion.

A large Indian business evaluating a software vendor is asking several questions simultaneously: Does this product work? Will this company support it when something goes wrong? Will this company still exist in two years? A price that feels dramatically low raises all three questions without answering any of them. The buyer’s inference is not that they are getting a good deal. The inference is that something might be wrong.

This is not unique to India, but it is more pronounced in Indian enterprise markets where the consequences of a failed vendor relationship are social as well as financial. A CFO who approved a vendor that failed has a problem that is visible inside the organization. The price they paid is part of that story.

Pricing to the value you deliver, rather than to the floor of what you believe the market will accept, is not just a revenue decision. It is a credibility decision. The two are more connected in India than most pricing frameworks acknowledge.

The Pilot Trap

Indian enterprise buyers ask for pilots. This is reasonable: they are evaluating an unknown vendor on a problem that matters. A pilot is how they manage that risk.

What is less reasonable, and more common, is the pilot with no defined end point and no conversion criteria. A free pilot of indefinite duration is not a pilot. It is a free subscription with the expectation managed on the buyer’s side and the cost borne entirely by the seller.

The founders who have seen this pattern a few times know what it looks like: four to six months of positive feedback, a growing list of internal users who love the product, enthusiastic check-in calls, and no commercial conversation. The pilot has become the relationship. The buyer has no incentive to convert it into a contract because the current arrangement is already giving them everything they need.

The correction is to charge for the pilot. Not a commercial rate, but a real number that requires an actual purchase order or bank transfer. Even a nominal paid pilot changes the dynamic in a specific way: it has required the buyer to involve their finance or procurement function. Someone has approved the expenditure. There is now a stakeholder inside the buying organization who has made a decision about this vendor, and that person has an interest in seeing the pilot conclude one way or another.

Conversion rates from paid pilots to commercial contracts are substantially higher than from free pilots. The explanation is not that paying unlocks goodwill. It is that a financial commitment, however small, forces organizational seriousness that a free engagement does not.

The Price Travels Through the Market

When a large or prominent customer signs at a significantly reduced price, that price often does not stay private.

Indian business communities, particularly within specific industries, are more connected than they appear from the outside. The textiles cluster in Surat, the gems and jewelry community in Mumbai, the automotive ancillary suppliers in Pune: these are communities where people talk, where the procurement head at one company knows her counterpart at a competitor, and where information about what vendors charge moves through the network.

A founder who prices a large conglomerate at 40 percent below list to win the account may find, within 12 to 18 months, that every other prospect in that industry has the same number in mind when the sales conversation starts. The discount has become the market price.

The version of this that compounds fastest is when a marquee customer is given free access in exchange for a reference or a case study. The reference often does not materialize, for reasons that have nothing to do with satisfaction: the internal champion moves roles, the legal team declines to allow public commentary, the company’s communications policies change. The free access remains. And the market knows that a name-brand company is using the product at zero cost.

The more durable approach with marquee customers is to charge a real price and invest in their success. A customer who paid fairly and had an excellent experience is a stronger reference than a customer who got a steep discount and is privately uncertain whether they would have paid commercial rates.

The Budget Cycle Most Founders Do Not Account For

India’s corporate fiscal year runs April to March. This is not a trivial detail. It shapes the entire rhythm of enterprise purchasing in ways that directly affect how deals close and when.

Large Indian enterprises set technology budgets in January and February for the fiscal year beginning in April. By October, most budget has been allocated. A deal that surfaces in November is almost always competing for unallocated budget from the current year or pre-selling against next year’s cycle. Both conversations are harder than they look.

The timing implication for founders: the most productive windows for enterprise sales in India are April through June (new budget, fresh priorities) and September through October (Q2 close, before year-end planning begins). Deals initiated in November and December often stall not because of product or price objections, but because the organizational machinery for approving new spend has slowed for the year.

Understanding this cycle also clarifies why some deals seem to move quickly and others take forever despite similar levels of enthusiasm. The prospect who is enthusiastic in August is working within active budget. The equally enthusiastic prospect in November is asking you to either compete for end-of-year unallocated funds or wait.

The Champion and the CFO Are Different Conversations

In Indian enterprise, the person who is most enthusiastic about your product is frequently not the person who controls the budget.

A supply chain head who wants your inventory management software has to convince a CFO who thinks about headcount, balance sheets, and the cost of changing systems. A marketing director who wants your analytics product has to convince a procurement team that evaluates vendors on stability and compliance criteria as much as on product quality. The internal champion and the budget authority are different people with different concerns, and pricing that works for one often does not work for the other.

The specific failure mode is pricing in a way that makes sense to the champion but does not give them the language to make the case to their CFO. A CFO evaluating a software purchase is asking a different set of questions than a functional head. They want to know: what happens to headcount? What is the three-year TCO? What is the risk if the vendor fails? What does this cost compared to what we currently spend?

Pricing that is designed to clear the CFO’s questions, not just the champion’s enthusiasm, closes faster. This means having a clear number for what the product replaces in cost terms, a total cost of ownership calculation that survives scrutiny, and a commercial structure (annual contract, clear implementation scope, defined support terms) that the CFO can defend internally.

Seat-Based Pricing Often Fails in Indian SMBs

In Indian small businesses, seat-based pricing runs into a specific behavioral reality: credential sharing.

A small business owner who is being charged per user will, very often, create one account and have multiple employees use it. This is not piracy in the way they think about it. It is the same mental model that governs sharing a cable subscription or a newspaper. One purchase, shared benefit.

This behavior means that seat-based pricing systematically underestimates usage and, critically, gives the founder no visibility into how widely the product is actually adopted within the customer’s organization. A customer who shows as one seat may have eight people using the product daily. When that customer churns, the real loss is eight users’ worth of embedded value, not one.

Per-transaction or per-outcome pricing sidesteps this problem entirely. The customer does not think about seats. They think about usage, and usage is what generates the bill. The founder gets accurate signal about adoption and a pricing model that scales with value delivered.

For products where per-outcome pricing does not fit the product structure, usage-based tiers (light, standard, heavy) based on actions or outputs rather than named users often work better in Indian SMB than pure seat counts.

Price Sensitivity Is Not Uniform Within a Category

Indian market analysis often treats price sensitivity as a feature of a buyer segment. SMBs are price-sensitive. Enterprise is less price-sensitive. This is a starting point, not a conclusion.

Within any segment, willingness to pay varies dramatically based on what is at stake if the problem is not solved.

Consider accounting software. The average Indian SMB might resist paying ₹3,000 per month for accounting software because the consequence of managing accounts manually is inconvenience and some time lost. The same SMB that has recently received a GST scrutiny notice will pay multiples of that immediately, because the consequence of getting accounts wrong has become reputational and legal risk.

Consider logistics software. A transporter who moves ordinary consumer goods may resist paying for a digital dispatch system. A transporter who moves pharmaceutical cold chain or high-value electronics, where a lost or delayed shipment means a contract termination, will pay significantly more because the cost of failure is asymmetric.

The implication for founders is that the same product can command very different prices depending on which version of the customer’s problem you are solving. The customer who has already been burned by the failure mode your product prevents is the easiest sale and the highest-value customer. Finding that customer, and pricing to the risk they are trying to eliminate rather than to the average willingness to pay in the segment, is one of the most underused approaches in Indian B2B pricing.

One Community Customer Can Make the Next Twenty Free to Acquire

This dynamic is specific to Indian markets and significantly undervalued in how founders think about early pricing.

Indian B2B markets in specific geographies and industries are genuinely community-structured. The diamond traders of Surat, the cotton ginners of Vidarbha, the auto component manufacturers of the Pune-Nashik corridor: these are industries where buyers know each other, trust each other’s recommendations, and frequently make adoption decisions as a community rather than independently.

In these markets, one genuine success story from a trusted peer is worth more than any amount of outbound sales or product marketing. A founder who acquires the right first customer in a community, invests heavily in making that customer successful, and creates conditions for that customer to talk about the product, will find that the second and third and tenth customer in the same community require almost no sales effort.

The pricing implication is that the first customer in a community is not just a revenue decision. It is a distribution decision. Spending more on that customer’s success, whether through implementation support, dedicated attention, or a slightly better commercial arrangement in the early stage, is not a cost of sale. It is a cost of distribution into the community. The economics of the arrangement look very different when you account for the customers it unlocks.

Frequently Asked Questions

Should Indian SaaS companies price lower than their US equivalents?

The right reference point is not the US price discounted for purchasing power. It is what the customer currently spends on the problem. In many Indian B2B categories, that number is the cost of the people doing the process manually. Understanding that number before setting a price tends to produce figures that are higher than founders assume the market will bear.

When does freemium work in India?

When adoption is individual-level and the product spreads virally through organizations. Developer tools, collaboration software, and products where one user inviting others generates organic growth can work on freemium in India. B2B products where the buying decision is organizational rarely convert well from free. A time-limited trial with a defined conversion moment usually outperforms a permanent free tier for organizational buyers.

How should founders handle requests for free pilots?

By charging for them, even nominally. A paid pilot requires the buyer to involve procurement or finance, which creates internal stakeholders with an interest in seeing the evaluation conclude. Free pilots with no end point frequently become free subscriptions.

What is the right way to handle discounting?

Every discount should have a documented rationale and a defined time limit. Volume commitment, annual billing, early customer status. Undocumented discounts become expectations, travel through market networks, and create a chaotic pricing history that is difficult to explain at Series A.

Does the fiscal year matter for enterprise sales timing?

Significantly. Indian enterprise budgets are set for April-March. The highest-velocity windows for enterprise deals are April through June and September through October. Deals initiated in November and December frequently stall because of budget cycle dynamics rather than product or price objections.

How to Sell to Indian SMBs

Posted on July 15, 2026July 16, 2026 by Kae Team

Selling to Indian SMBs is one of the largest and most misunderstood opportunities in the country.

The scale is well known. Roughly 63 million MSMEs, digitising fast, generating a growing share of India’s non-metro GDP. What is less understood is what actually converts an SMB buyer, and why so much of the standard advice on this market travels poorly.

Most playbooks that circulate are borrowed. Some come from enterprise SaaS. Some from consumer software. Some from writers who have never sat across a desk from a textile trader in Surat. None fit the Indian SMB cleanly, and the reasons are structural. The Indian SMB is not a smaller enterprise. It is not a business version of a consumer. It is a third kind of buyer, with its own decision cycle, its own trust mechanism, its own willingness to pay, and its own distribution reality.

Five principles below, drawn from patterns we have watched inside our portfolio and across the broader ecosystem. None are theoretical. All are things founders eventually learn on the ground. The point of writing them down is to shorten the curve.

Who we mean by “Indian SMB”

India has 63 million MSMEs. That number, on its own, is not very useful for product decisions. It stretches from the paan shop on the corner to a 400-crore auto-component manufacturer in Pune.

The addressable slice that venture-backed SaaS can realistically serve is roughly 2 to 3 million businesses. Owner-operated, 5 to 100 employees, revenue between 50 lakh and 50 crore, digitally adjacent (UPI, WhatsApp, sometimes Tally). The rest of the 63 million is a critical part of the Indian economy but requires a different model to reach: usually one where credit, commerce, or agent networks carry the cost of the software layer.

Five principles

1. The buying committee is bigger than you think

Nominally, one person runs the SMB. In practice, three to five people vote on any purchase above five thousand rupees a year. The owner. The spouse. The chartered accountant. The son or daughter being groomed. Sometimes a trusted peer in the community. Any one of them can kill the deal.

The chartered accountant is the highest-leverage of these voices. India has roughly 400,000 practising CAs, and every SMB defers to theirs on anything involving money, tax, compliance, or software. Vyapar and TallyPrime dominate not because their software is dramatically better but because every CA in India recommends them by reflex. Zoho Books built its India traction by making the CA the primary evangelist. If your product does not have a CA channel strategy on day one, you are competing with one hand tied.

Practical test: talk to twenty CAs before your seed round. If they cannot see why they would recommend the product to their SMB clients, redesign it.

2. Trust is a physical object

Enterprise buyers accept remote sales. Consumer buyers accept self-serve. The Indian SMB owner needs to see something physical. A local salesperson. A demo across a desk. A reference customer at the trade association meeting.

The channels that work: CA networks, trade associations (textile, jewellery, engineering, packaging), community networks (Marwari, Gujarati, Sindhi, Chettiar), franchise and agent models, in-market events. BharatPe’s early growth was not advertising. It was feet-on-street agents in Karol Bagh and Chandni Chowk, one merchant at a time.

The channels that do not work at scale: LinkedIn ads (LinkedIn is for salaried professionals, not owner-operators), Google Ads for generic SMB queries (mostly click farms), cold email (Indian SMB owners read WhatsApp, not inbox), and content marketing to English-speaking audiences (fine for building CA brand, wrong for the actual buyer).

3. Everyone underprices

The instinct is to price low because “SMBs won’t pay.” It is usually wrong. Indian SMB owners have a sharp sense of value. They pay 50,000 rupees a month to a good CA. They pay 25,000 a year for a Tally licence. They pay 100,000 for a security camera setup. What they will not pay is 500 rupees a month for something that feels like a nice-to-have.

Better structures: one clear annual price in the 5,000 to 25,000 rupee range, cash discount of 10 to 15 percent for annual upfront, one plan not four. Auto-debit adoption in Indian SMB is under 20 percent, so the US SaaS card-on-file model will not carry your renewals. Design for a renewal conversation, not an autopay pull.

Freemium works only if the free tier is a genuine funnel. In most Indian SMB categories, the free tier becomes the product and paid conversion stays under 3 percent.

4. Support is the product

Enterprise support is a ticketing system. Consumer support is a chatbot. Indian SMB support is WhatsApp. In-language. Human. Fast.

Khatabook built its user base on Hindi WhatsApp support that answered within thirty minutes. BharatPe put voice support in Indian languages at the centre of the merchant relationship. Refrens, Vyapar, and every winning SMB product has treated support as strategic, not a cost centre.

Cost math: an agent capable of Hindi, one South Indian language, and English costs 5 to 8 lakh a year fully loaded, and retains 400 to 600 customers annually if the product is stable. This works if the product is priced correctly. Founders who under-invest in support and over-invest in acquisition end up with high CAC, poor retention, and no idea what customers actually want.

5. The second sale is the real business

The first sale to an Indian SMB is a favour. The renewal, the upsell, and the referral are the actual business. Retention, when the product delivers, is remarkably sticky. An SMB owner who has trusted a product with their books, their payments, or their compliance does not casually switch. Lifetime values of five to seven years are common. Ten to fifteen is not rare.

But renewal is not automatic. Thirty days before expiry, someone on your team needs to WhatsApp the customer, share a summary of what the product has done in the last year, and invoice for the next twelve months. Skip this and happy customers churn out of forgetfulness.

The best Indian SMB companies are stack businesses. They land on one product (accounting, payments, invoicing) and expand into two or three adjacent ones over three to five years. Accounting to payments to credit to insurance is the pattern that keeps working. Founders who plan the stack from day one, but ship one product at a time, compound faster than founders who bolt on services later.

What Kae looks for

The founders who win in SMB can describe the target buyer’s family, not just the job title. Home town. Frustration with the incumbent tool. Sunday routine. That kind of specificity comes from either growing up in a business family or spending two to three years working inside the industry before starting. Secondary research from a Bengaluru office does not close the gap.

Beyond that, the pattern we back: a specific answer to “how do you reach the first 500 customers” that is not “Meta ads and content marketing”, a retention thesis before an acquisition thesis, a pricing number tested against what the buyer already pays for adjacent services, and a support model treated as strategic, not overhead.

The Indian SMB market is not getting easier. The buyer is still relational, still risk-averse, still under-served by imported playbooks. What is changing is the infrastructure. GST digitisation, UPI ubiquity, Account Aggregator, and a second generation of digitally-fluent owner-operators are all now real. The founders who understand this are compounding quietly. The ones who do not are running the same enterprise-lite motion that has failed for a decade.

What To Build: Healthtech

Posted on July 1, 2026July 1, 2026 by Kae Team

Part three of a series. We did consumer AI first because the anxiety was loudest, fintech second because the opportunity was least understood. We are doing healthtech third because almost everyone gets this category wrong and the prize for getting it right is the largest of the three.

The reflex says healthtech is hard. The reflex is right and wrong.

For fifteen years, Indian healthtech has been structurally hard. Telemedicine ran into unit economics that did not work at scale. Pharmacy apps competed away their margins on a commoditised SKU set. Health insurance lived inside opaque sales channels that no software layer fully fixed. Hospital chains needed patience that most venture capital did not have. The 2021 boom inflated valuations the 2023 reset took back down. A lot of good founders took the shot; the structural realities held them back.

The reflex this produced is “healthtech is too hard in India. Skip the category.” That reflex is right about the playbook of the last decade and badly wrong about the next one. The shape of the opportunity has changed in five specific ways that almost no one has internalised.

First, the infrastructure caught up. The Ayushman Bharat Digital Mission now has 760 million health accounts and ABHA IDs are being linked across hospitals, diagnostics, and pharmacies. The second phase, rolling through 2026, mandates cloud-first data sharing and ABHA integration for any hospital larger than 50 beds. The interoperability layer that took the United States twenty years to half-build, India is shipping in five.

Second, the economics caught up. Continuous glucose monitors crossed below 3,000 rupees per sensor in 2025. Whole genome sequencing dropped below 200 dollars in 2026 thanks to government-backed Biopharma SHAKTI investments. Wearable BP monitors, ECG patches, pulse oximeters, and connected scales are all in the affordable consumer range. The “rich-person tech” of 2020 is now mass-market hardware.

Third, the regulation caught up. 100 percent FDI in insurance opened up annuity and outcome-based product design. The DPDP Act formalised health data consent. IRDAI’s 2025 framework allowed embedded and parametric health insurance. The CDSCO software-as-medical-device guidelines clarified what an AI clinical tool can and cannot claim. These are not perfect rules, but they are real rules, and ambiguous regulation has historically been the single biggest blocker for Indian healthtech.

Fourth, the AI got useful. AI radiology, AI pathology, ambient clinical scribing, voice-driven triage, and decision support for the GP are all crossing usable thresholds in 2026. Qure.ai and Niramai are exporting Indian-built diagnostic AI globally. AIIMS deployed AI research centres across 22 campuses. The Indian government has put more than a billion dollars behind AI in healthcare. This was not the situation eighteen months ago.

Fifth, the capital noticed the asset-light hospital model. The Indian asset-light hospital services market is growing at roughly 30 percent CAGR. Single-specialty chains in IVF, oncology, and nephrology pulled in 1.4 billion dollars in PE in the last 24 months. HCG raised 425 crore in FY26 alone to expand precision oncology. The era of building a 500-crore multispecialty hospital and waiting fifteen years for ROI is being replaced by smaller, focused, high-throughput models.

Put it together and India in 2026 has the digital backbone, the affordable hardware, the workable rules, the credible AI, and the new asset-light playbook. None of those existed at once before. The ideas below are the products to build on top of that stack.

A note before the list. Healthtech rewards depth in one place and punishes generalism. Most of these ideas are not “platforms”; they are care companies, clinical products, or operationally heavy businesses. We have tried to be specific about which is which. The teams that win in this category are typically two-founder pairs where one founder is a real clinician or operator and the other is a real builder. If you do not have the clinician half of the team, fix that before you raise.

If you are building one of the twenty below, or a sharper version of one, come talk to us.

1. The next India pharmacy

Tata 1mg, Apollo 24/7, PharmEasy, Netmeds. The first wave built distribution, then ran into thin margins on a commoditised SKU set. The next pharmacy is not a delivery business; it is a care relationship that happens to dispense medicine.

Build a pharmacy that knows the patient. The wedge is chronic disease cohorts: hypertensives, diabetics, post-MI patients, asthmatics. Each customer is on three to seven prescriptions for years. The product is a subscription that includes the medication, an adherence layer, monthly check-ins with a pharmacist, refill orchestration synced to the doctor visit, and proactive flags when something is off. Margins compound through retention, not through paid acquisition.

Why now: ABHA integration means the pharmacy can see the actual prescription history, not just the current refill. Connected devices feed back vitals. The retention curve of a chronic patient is dramatically longer than the average e-commerce buyer.

Who wins: a pharmacist or clinician founder paired with a strong consumer product team. Operators who have run an actual pharmacy chain, not generic D2C founders.

Watch-outs: do not chase the entire pharmacy market. The acute one-time customer (a course of antibiotics) is unprofitable. Pick the chronic patient and build the loyalty engine specifically for them.

2. Diagnostics-first health membership

Tata 1mg, Healthians, Redcliffe, and Apollo Diagnostics each do millions of tests a year. The customer relationship ends when the report is delivered. The result sits in WhatsApp, gets shown to a GP once, and disappears. The next product treats diagnostics as the start of the relationship, not the end.

Build a diagnostics-led health membership. Annual or quarterly subscription that includes a baseline panel, longitudinal tracking, a personal health doctor who reads the results, lifestyle and supplement recommendations, and a clear escalation path if something is off. The bet is that 8 to 12 percent of users will discover something actionable in any given year, and the product becomes the trusted layer between the user and the clinical system.

Why now: lab automation has driven test prices down 60 to 80 percent in five years. CGMs, ECGs, and at-home blood draws make the data flow continuous, not episodic. ABHA-linked records make longitudinal tracking possible for the first time.

Who wins: a founder who can run both the operational lab side and the clinical content side. A pure consumer founder gets the experience right but fails at the lab cost structure. A pure lab founder fails at retention.

Watch-outs: do not become an insurance product by accident. Selling membership that pays for tests blurs into insurance regulation. Stay clearly on the wellness and prevention side or get an insurance licence.

3. Women’s health, expanded beyond PCOS

Women’s health in India has historically meant maternity (the institutional model) or PCOS (the recent D2C wave). Both leave huge gaps. The full lifecycle of an Indian woman, from puberty through fertility planning through menopause through bone health and cardiovascular care in her 50s and 60s, is not served by a single trusted product.

Build a women’s health platform that follows the user across decades. Adolescent care (PCOS screening, mental health, contraception). Pre-conception and fertility planning. Pregnancy and postpartum, but as a longitudinal product, not a one-time event. Perimenopause and menopause (Indian women experience menopause five to seven years earlier than Western cohorts; the data and the products are both inadequate). Bone, thyroid, and cardiovascular care in later decades. Each life stage is a different product feature; the platform is the relationship.

Why now: women’s health has become a real venture category in 2025 and 2026. Maven, Tia, and Hertility in the US have proven the model. India needs the version that handles the joint family, in-law, and clinical access realities that Western products ignore.

Who wins: a female founder pair with deep credibility, ideally one a clinician (gynaecologist or endocrinologist) and one a consumer builder.

Watch-outs: do not market as “wellness.” Indian women are sophisticated consumers of clinical care and are insulted by wellness-light positioning. Lead with clinical credibility.

4. The IVF and fertility chain, reimagined

The Indian fertility market is roughly 1.5 billion dollars and growing at 18 to 20 percent CAGR. Indira IVF runs 140-plus centres. Nova IVF, Birla Fertility, and ART have scaled. The category is consolidating, but the patient experience remains medieval. Couples spend 2 to 8 lakh per cycle, often for two or three cycles, with success rates that vary wildly and almost no transparency.

Build an IVF and fertility chain that competes on outcomes and experience, not on advertising. Standardise the protocol. Publish honest cycle success rates per age cohort. Use AI in embryo selection and ovarian stimulation protocols (early evidence shows materially improved live-birth rates). Include the male-factor workup as default, not afterthought. Bundle psychological care across the brutal emotional arc.

Why now: AI in embryo selection (companies like Alife, Embryonics, and Avenir genetics) has moved from research to deployment. Indian fertility patients are increasingly digital-native and informed; the days of patriarchal “trust the doctor” are ending.

Who wins: a clinician (reproductive endocrinologist) plus a strong operator. This is a clinic chain, not a software business.

Watch-outs: do not race to scale by adding low-quality clinics. The category’s reputation is fragile, and one botched cycle that goes viral on Instagram can damage the brand for a decade.

5. Pediatric primary care, redesigned

Indian families spend hundreds of thousands of rupees on schooling, then take their child to the GP next door for everything from a fever to a developmental concern. The pediatric primary care layer is fragmented, often staffed by general practitioners with limited pediatric training, and rarely longitudinal. The Indian middle class will pay for better.

Build a pediatric primary care company. Physical clinics in residential dense pockets of tier 1 cities, complemented by a digital layer. Pediatricians, not GPs. Vaccinations, developmental milestone tracking, behavioural and learning concerns, nutrition, sleep, common illness, and chronic conditions like asthma and allergies. Each child has a longitudinal health record from birth to adolescence. Membership pricing per child.

Why now: tier 1 family incomes have grown materially. Willingness to pay for premium pediatric care is the highest in 20 years. Connected devices (thermometers, otoscopes, etc.) reduce visit friction.

Who wins: a pediatrician with operator instincts paired with a consumer product founder.

Watch-outs: clinic-led healthtech needs real estate discipline and per-clinic unit economics that work standalone. Do not subsidise clinics with venture money expecting later monetisation. Each clinic must pay back in 24 to 36 months.

6. Mental health for kids and teens

The mental health crisis among Indian children and adolescents is real and largely invisible. School counsellors are under-resourced, parents are reluctant to engage, and the clinical system has almost no infrastructure for this cohort. Suicide is now the leading cause of death for Indian adolescents in many states. The category exists in research papers and almost nowhere as a product.

Build a clinical mental health product for Indian children and adolescents aged 8 to 18. School partnerships as the primary distribution. Trained clinicians (paediatric psychologists and psychiatrists) doing structured CBT, family therapy, and crisis intervention. AI-supported screening to identify at-risk kids. Parent and teacher coaching. Crisis pathways including suicidal ideation protocols. This is a clinical operation with a software layer, not the reverse.

Why now: post-pandemic mental health awareness in Indian schools jumped substantially. The CBSE 2024 advisory on mental health screening created institutional demand. AI-supported triage and clinician productivity tools are finally credible.

Who wins: a clinical child psychologist who has run a real practice, paired with a B2B founder who can sell to school networks. School distribution is half the product.

Watch-outs: child mental health is the highest-stakes category in this list. Build the clinical governance, supervision, and escalation pathways before you build growth. One avoidable adverse event sets the category back five years.

7. AI-driven home healthcare

Portea pioneered home healthcare in India a decade ago and the category has plateaued. The reasons are operational, not demand-side. Skilled nursing supply is tight, scheduling is messy, and quality varies hugely. AI can fix most of the operational pain that has held the category back, while demand is structurally accelerating as the over-60 population reaches 150 million.

Build an AI-native home healthcare company. The product is two halves. The B2C half handles post-operative recovery, chronic care, elderly care, palliative care, and physiotherapy at home. The B2B half is the operational AI: scheduling, route optimisation, real-time triage of nurse-to-clinical-supervisor escalations, electronic documentation that flows back to the hospital and insurer, and predictive analytics on patient deterioration. The latter is what makes the former actually work at scale.

Why now: voice-driven documentation finally works in Indian languages, removing a major time sink for home health nurses. Connected monitoring devices stream into the platform. The over-60 cohort is at structural scale.

Who wins: an operator who has run a home health business and seen the operational failure modes, paired with a strong AI engineering team.

Watch-outs: do not over-index on the consumer brand. The actual moat is the operational software and the nurse network. Companies that spent on brand and skimped on ops never crossed the chasm.

8. Vision and dental for Bharat

Lenskart proved the model for vision and is now valued accordingly. Clove and Toothsi have made early progress in dental. Both categories are massively underpenetrated in tier 2, tier 3, and rural India. Vision: roughly half of Indians who need glasses do not have them. Dental: only 1 percent of India’s 5 lakh dentists practise in tier 2 and below.

Build a vision or dental chain designed for Bharat from day one. Smaller-format clinics in tier 2 and tier 3 cities. Lower price points, payment plans, group discounts via employers and government schemes. Telehealth backbone for triage and follow-up. Standardised protocols. Use vans or pop-up camps to reach district headquarters that cannot support a permanent clinic.

Why now: the Lenskart playbook validated that the consumer optical category is large enough. Government and employer-funded health schemes increasingly cover vision and dental basics. Last-mile logistics in tier 2 and 3 has improved substantially through Delhivery, Ecom Express, and Shadowfax.

Who wins: a founder who has built a chain in any consumer category and understands tier 2 unit economics. Healthcare-only founders typically underestimate retail.

Watch-outs: each clinic must be standalone-profitable within twelve months. Do not let a few showcase clinics in metros fool you into believing the model works. Tier 2 is the test.

9. Teledermatology with AI triage

Indian dermatology runs on two tracks. The metro track is over-supplied with cosmetic-led clinics. The tier 2 and rural track is starved; the average district has fewer than ten qualified dermatologists. Skin conditions including acne, eczema, fungal infections, and chronic dermatoses affect tens of millions, and most never see a specialist. Tele-derm is the obvious answer and has been attempted, but never well.

Build an AI-augmented tele-dermatology company. The user uploads images. An AI model trained on Indian skin tones (note: most existing models are not) generates a preliminary triage. A qualified dermatologist reviews and confirms within hours. Treatment plan, prescription, and over-the-counter product recommendations follow. Recurring follow-up via the app. Distribution through GP networks and pharmacies in tier 2.

Why now: image-based dermatology models calibrated to Indian skin tones have started shipping in 2025. The cost of a tele-consult is finally below what a tier 2 family will pay out of pocket.

Who wins: a dermatologist co-founder is non-negotiable. The other co-founder needs a strong consumer product or AI background.

Watch-outs: do not become a pharmacy in disguise. The temptation to push high-margin OTC products will compromise clinical trust. The product is the diagnosis and the relationship; the medication is the side effect.

10. AI radiologist for tier 2 and 3

India has roughly 15,000 trained radiologists serving 1.4 billion people. The shortage is acute in tier 2 and 3, where many small hospitals run imaging machines without a full-time radiologist; films get sent to a metro radiologist with a 24 to 72 hour turnaround. AI-assisted radiology has been the most clinically validated application of medical AI globally and the time-to-deploy in India is now.

Build a teleradiology and AI radiology product targeted at tier 2 and 3 hospitals and diagnostic centres. The AI flags critical findings (intracranial bleeds, pulmonary embolism, fractures) in real time. A network of radiologists reviews and signs off remotely with workflow optimisation. Critical findings escalate within minutes; routine reads come back within hours. Pricing per study or per month, with hospital integration via DICOM.

Why now: Qure.ai and a handful of others have already proven the FDA, EU, and India regulatory pathway. India’s 22-campus AIIMS AI deployment validates clinical credibility. Hospitals in tier 2 are actively shopping for the integrated stack.

Who wins: a radiologist plus a strong machine learning team. The clinical workflow nuance matters more than the model.

Watch-outs: liability is the entire business. A missed cancer or a missed bleed is a career-ending event. Build clinical governance, escalation pathways, and second-read protocols from day one.

11. AI pathologist for cancer screening

Cervical, breast, and oral cancer screening at scale in India is gated by the shortage of trained cytopathologists. Government programmes have tried to deploy screening; the bottleneck is reading the slides. AI for pathology image analysis has matured to the point of clinical viability, and India is a natural deployment ground.

Build an AI-pathology company focused on cancer screening at population scale. Partner with diagnostic chains, public health programmes, and tier 2 hospitals. Slides are digitised once and read by AI in minutes, with pathologist sign-off for positives. The economic model can support population-level screening that human-only workflows never could. The wedge can be cervical (HPV-driven, well-validated AI), breast (mammography and FNAC), or oral (smartphone-camera-based screening for high-risk cohorts including tobacco users).

Why now: digital pathology hardware costs collapsed in the last 36 months. AI accuracy in specific cancer types has crossed pathologist parity in published trials. The government’s cancer-screening push is creating institutional demand.

Who wins: a pathologist or oncologist plus a strong AI team. Distribution requires relationships with public health systems.

Watch-outs: regulatory clearance for autonomous AI diagnosis is not yet there in India. Design as “AI-assisted pathologist sign-off” not “AI alone.” Get the CDSCO classification right at the start.

12. The doctor copilot for OPD

Indian outpatient practice runs on three-minute consultations and handwritten prescriptions. Doctors lose 30 to 40 percent of their time to documentation, prescription writing, follow-up reminders, and basic patient communication. None of this is value-added clinical work. AI ambient scribing, prescription generation, and patient communication tools, calibrated for Indian languages and the actual OPD workflow, are a massive opportunity.

Build a doctor copilot product. Voice-driven ambient documentation that listens to the consultation, extracts the clinical note, generates the prescription in the doctor’s preferred format, and pushes the follow-up reminder to the patient. Multilingual (Hindi, Tamil, Telugu, Marathi, Bengali, plus English). Integrates with the doctor’s existing EMR or replaces it for solo practitioners. Pricing per doctor per month.

Why now: voice transcription in Indian languages crossed clinical utility in 2025. Indian doctors are willing buyers; international scribing tools (Abridge, Augmedix, Suki) have validated the global appetite. The Indian market needs the local-language and local-format version.

Who wins: a founder pair where one is a practising physician (the product depth is non-trivial) and the other is a strong AI or product founder.

Watch-outs: do not bolt on too many features. The best version of this is ruthlessly focused on saving doctor time. Adoption is the only metric that matters. Engagement KPIs are misleading.

13. AI for hospital revenue cycle and operations

Indian hospitals lose 15 to 25 percent of their revenue to claims rejection, denied insurance reimbursements, missed billing, and operational inefficiency. Revenue cycle management software in the US is a multi-billion-dollar category (Waystar, R1 RCM, Olive). India has the same problem with much weaker software.

Build a hospital RCM and ops platform. Claims-aware billing that pre-checks insurance policies in real time. Pre-authorisation workflows that talk to TPAs directly. Denial management with AI that pulls the exact regulatory or contractual reason and pushes for resubmission. OT and bed-management optimisation. Discharge summary generation. Pricing as a percentage of additional revenue recovered.

Why now: ABHA-driven interoperability removes a major data plumbing problem. The IRDAI claims framework standardised in 2025 reduces the integration burden. Hospitals are facing margin compression and are actively shopping.

Who wins: a B2B founder with hospital sales experience, paired with a strong product and engineering team. Selling to Indian hospitals is a known hard problem; you cannot fake the relationship layer.

Watch-outs: the sales cycle is brutal. Plan a 9 to 12 month enterprise sales cycle. Founders who promised three-month sales got embarrassed.

14. PBM and corporate health benefits

Indian employers spend roughly 25,000 crore annually on corporate health insurance and employee wellness. The category is dominated by traditional brokers (Marsh, Aon, Plum) and a handful of digital first movers (Plum, Onsurity). Nobody has built the actual PBM (pharmacy benefit manager) and care navigation layer that the US matured 30 years ago. The Indian employer is ready for it.

Build a PBM and benefits product. Integrate with the employer’s insurance broker. Negotiate pharmacy and diagnostic prices across the employee base. Steer employees to high-quality providers with transparent pricing. Manage chronic care for high-cost employees (diabetes, mental health, cardiovascular). Telehealth and second opinion. Reporting back to the employer on cost trend and outcomes.

Why now: 100 percent FDI in insurance has changed insurer behaviour around outcome-based deals. Large Indian employers (TCS, Infosys, Reliance, the major banks) are actively asking for this product after seeing US PBM models.

Who wins: a founder pair with deep insurance or PBM domain knowledge plus enterprise sales. Plum and Onsurity will compete; the wedge is depth on care navigation, not just insurance.

Watch-outs: PBMs in the US are deeply problematic businesses with serious conflicts of interest. The Indian version has the chance to do this honestly. Lead with transparency or you become the thing you should not become.

15. Precision oncology and genomic testing

Whole genome sequencing crossed below 200 dollars per genome in India in 2026. NGS is moving from rare-disease and tertiary cancer into routine practice. Hospitals like HCG raised 425 crore in FY26 specifically to expand precision oncology infrastructure. The Indian NGS market is projected to hit 1.33 billion dollars by 2033.

Build a precision oncology and genomic testing company. The product is the diagnostic and the interpretation layer combined. Tumour profiling for actionable mutations, germline testing for hereditary cancer, pharmacogenomics for chemotherapy dose optimisation, and minimal residual disease monitoring. The pricing is per-test plus a recurring layer for longitudinal monitoring. Distribution through oncologist networks at the major hospital chains.

Why now: government Biopharma SHAKTI investments cut the cost of sequencing. CDSCO clearance for several NGS panels landed in 2025 and early 2026. Oncologists are increasingly trained to act on molecular results, having historically been more conservative.

Who wins: an oncologist or molecular biologist with deep clinical credibility, paired with a strong commercial founder. The hard part is convincing oncologists to use the test and act on the result, not the sequencing itself.

Watch-outs: do not build only the diagnostic without the interpretation. A raw NGS report sent to an oncologist who cannot read it is worse than no report. The interpretation and treatment recommendation layer is the actual product.

16. Cancer care navigation

A cancer diagnosis triggers a chaotic two-to-five-year journey across oncologists, surgeons, radiation centres, chemotherapy infusions, palliative care, and increasingly genomics. Indian patients lose months to coordination failures, wrong sequencing of treatments, and second opinions that come too late. The category in the US has spawned companies like Color Health (now valued at over 1.5 billion) and Thyme Care. India has nothing equivalent.

Build a cancer care navigation company. The product is a clinical and operational layer between the patient and the fragmented system. Care coordinator (clinically trained) assigned per patient. Treatment plan review by a tumour board. Second opinion access to leading oncologists. Logistics support (travel, accommodation, financial counselling). Insurance and claims handling. Continuous symptom tracking and chemo side-effect support. Genomic and clinical trial matching where relevant.

Why now: the Indian cancer incidence is rising sharply, with 1.5 million new cases annually. Employer interest in offering this as a benefit has materialised in 2025 and 2026. Insurance companies are interested in the cost-savings story.

Who wins: an oncologist or oncology-care veteran with credibility, plus a strong consumer or B2B founder depending on go-to-market.

Watch-outs: this is heavy operational work, not a software business. The team has to be willing to be in the trenches with patients. Founders who underestimate that have failed.

17. The asset-light hospital chain

The classic 500-crore multispecialty hospital has been a poor venture investment for two decades. The new model, validated by Indian PE in the last 24 months, is the asset-light single-specialty chain. IVF (Indira IVF), cardiac (Asian Heart, KIMS), oncology (HCG), and renal (NephroPlus) have all shown the model works. The category is growing at roughly 30 percent CAGR.

Build a single-specialty hospital chain. Pick one specialty that is high volume, standardisable, and not already dominated. Strong candidates: ENT and audiology, ophthalmology surgery (cataract is at 75 million annual procedures globally), orthopaedic day-care (knee and hip), pain management, and gastroenterology. Asset-light means leased real estate, capex-efficient equipment, and protocol-driven clinical work. Replicable per-clinic unit economics within 18 to 30 months.

Why now: tier 1 and tier 2 demand is structurally there. PE money is actively chasing the model. The clinical talent supply has grown enough to staff replicable chains.

Who wins: a clinician with proven operating chops (someone who has run a hospital or clinic chain), paired with a real estate and operations partner.

Watch-outs: standardisation is the entire game. The chain that lets each clinic do things its own way collapses. The team has to be culturally comfortable with protocol-driven medicine, which is hard for some clinicians.

18. Senior and assisted living

India has 150 million people over the age of 60 and the cohort is growing faster than any other age group. Quality senior living and assisted living infrastructure is almost non-existent at scale. Antara, Athulya, and a handful of regional players have made starts; the category is wide open. The diaspora children of Indian seniors, in particular, are a high-willingness-to-pay buyer.

Build a senior and assisted living business. Three tiers can coexist. Independent living for the active 60-to-75 cohort (community, wellness, light medical). Assisted living for the 75-plus or limited-mobility cohort (more clinical, more nursing). Memory care for cognitive decline. Locations near tier 1 metros but in lower-cost peripheral pockets. Real estate light, operations heavy. The diaspora family is often the financial decision-maker.

Why now: the demographic shift is now undeniable. Diaspora willingness to pay has compounded for a decade. Tier 1 real estate in peripheral areas is acquirable at reasonable cost.

Who wins: an operator with hospitality, geriatric care, or hotel experience. Healthcare-only founders typically underestimate the residential experience side.

Watch-outs: regulatory frameworks for senior living in India are still maturing. Engage early. Trust is the entire business; one neglect or safety incident lands you on prime-time news.

19. Respiratory and allergy care

Roughly 100 million Indians live with chronic asthma, COPD, allergic rhinitis, or related respiratory conditions. Air pollution makes the situation structurally worse. The category is served by GPs, ENT specialists, and pulmonologists in fragmented practices, with no clear branded care company. This is one of the largest unmet chronic care needs in the country.

Build a respiratory and allergy care company. Diagnostic-first (allergy panels, spirometry, FeNO testing where indicated). Specialist consultation. Personalised treatment plans including environmental management, immunotherapy where appropriate, medication regimens, and digital monitoring of symptoms. Subscription-based membership for chronic patients. Bundle pediatric and adult cohorts under one brand. Distribute through schools (asthma screening), employers, and consumer marketing in polluted metros.

Why now: air quality awareness has crossed an inflection point in 2025 and 2026, with multiple Indian cities making global “worst air quality” lists routinely. Immunotherapy availability in India has expanded. Wearable spirometry is consumer-affordable.

Who wins: a pulmonologist or allergist with operating chops, paired with a strong consumer product founder.

Watch-outs: do not become a wellness brand selling air purifiers. The clinical care is the product; air purifier affiliate revenue is a distraction at best, a credibility risk at worst.

20. Wearables and remote patient monitoring

Continuous glucose monitors below 3,000 rupees. ECG patches at 5,000. Wearable BP cuffs that fit on a wrist. Connected scales. Pulse oximeters with cellular connectivity. The hardware is here. The software layer that turns this data into actual clinical decisions, in the right clinician’s hands, at the right time, is barely built in India.

Build a remote patient monitoring company. Two halves again: the consumer-facing side that handles device provisioning, data capture, and patient engagement, and the B2B side that delivers clinically actionable summaries to physicians and triggers escalations when needed. Disease-specific protocols: post-MI cardiac, diabetes, hypertension, post-surgical, pregnancy, chronic kidney disease. Insurance-paid for some cohorts, employer-paid for others, out-of-pocket for the rest.

Why now: the device costs are finally consumer-affordable. ABHA-linked clinical records make integration with the clinical workflow possible. Insurance and employer demand has materialised. CDSCO has clarified the regulatory pathway for connected health devices.

Who wins: a founder with clinical depth (cardiology or endocrinology ideally), paired with a hardware and integration engineering lead. Distribution through hospital chains, insurance partners, and direct.

Watch-outs: do not be a hardware company. The device is the entry point; the software, the analytics, and the clinical workflow are the product. Founders who fell in love with the device lost the company.

Picking one

Twenty ideas is a menu, not a strategy. Four filters for narrowing.

First, healthtech rewards depth in one place. Every successful Indian healthcare company is recognisable for one specific thing: Apollo for hospitals, Indira for IVF, Tata 1mg for pharmacy delivery, HCG for oncology. The companies that tried to be three things at once almost always lost. Pick one. Do it better than anyone else for five years before adding the second thing.

Second, the clinical co-founder is the product. Healthtech is the only category where the founder’s credibility with the medical community is sometimes more important than the product. A doctor founder builds trust ten times faster than a consumer founder. If your team does not have a clinician co-founder with real practice depth, fix that first. Hiring a medical advisor is not the same.

Third, regulation is not a barrier; it is a moat. The teams that engage with CDSCO, IRDAI, IRDAI, and the relevant medical councils early and seriously end up with a multi-year regulatory advantage. The teams that try to “move fast and apologise later” in healthcare hit walls. Indian regulators have remembered the Theranos lesson and are not patient.

Fourth, plan for ten years. Healthtech is a compounding business. Trust compounds. Clinical evidence compounds. Operating excellence compounds. Brand compounds. The teams that get this and the funds that support it patiently are the ones that win. Healthcare graveyards are full of three-year companies trying to be five-year companies.

A final note on the macro. Indian healthtech is at the rare moment where infrastructure (ABDM), capital (asset-light PE), regulation (IRDAI, CDSCO), demographics (aging), and AI capability are all aligned for the first time. Founders who saw 2013 to 2023 as proof that healthtech in India does not work are looking at the wrong data. The next decade rewards different founders, with different playbooks, building different companies. Build accordingly.

We will follow up with what to build in vertical AI SaaS next, then AI infra. If you are building one of the twenty above, or a sharper version of one, we want to hear from you.

The Kae Capital team. June 2026.

A note on intent: this is a thought piece, not an investment thesis. The ideas, categories, and companies discussed here do not necessarily reflect Kae’s active investment positioning or current portfolio. Nothing in this post should be read as a recommendation, solicitation, or commitment to invest. We write to surface ideas worth thinking about and to start conversations with builders, not to telegraph deals.